Compare MLYS & BHK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MLYS | BHK |
|---|---|---|
| Founded | 2019 | 2001 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Finance Companies |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.4B | 665.2M |
| IPO Year | 2023 | N/A |
| Metric | MLYS | BHK |
|---|---|---|
| Price | $23.91 | $9.12 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 6 | 0 |
| Target Price | ★ $48.67 | N/A |
| AVG Volume (30 Days) | ★ 1.1M | 327.0K |
| Earning Date | 03-12-2026 | 01-01-0001 |
| Dividend Yield | N/A | ★ 8.34% |
| EPS Growth | ★ 37.43 | N/A |
| EPS | N/A | ★ 1.03 |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $8.79 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $10.44 | $9.03 |
| 52 Week High | $47.65 | $11.00 |
| Indicator | MLYS | BHK |
|---|---|---|
| Relative Strength Index (RSI) | 32.15 | 33.92 |
| Support Level | $13.42 | $9.03 |
| Resistance Level | $31.09 | $9.72 |
| Average True Range (ATR) | 1.75 | 0.08 |
| MACD | -0.25 | -0.02 |
| Stochastic Oscillator | 14.59 | 20.51 |
Mineralys Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by abnormally elevated aldosterone. The company's product candidate, lorundrostat, is a proprietary, orally administered, selective aldosterone synthase inhibitor, that is initially developed for the treatment of patients with uncontrolled hypertension, defined as individuals who are unable to achieve BP of below 130/80 mmHg despite taking two or more lines of antihypertensive medication or resistant hypertension, typically including a diuretic.
Blackrock Core Bond Trust is a closed-ended management investment company. Its objective is to provide current income and capital appreciation. The trust seeks to achieve its investment objective by investing, under normal market conditions, at least 75% of its managed assets in bonds that are investment-grade quality at the time of investment. The trust, under a normal market scenario, will invest in a range of bonds, including corporate bonds, U.S. government and agency securities, and mortgage-related securities.